Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) Income towards Parent Company (2018 - 2025)

Historic Income towards Parent Company for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $24.3 million.

  • TransMedics' Income towards Parent Company rose 47711.1% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.8 million, marking a year-over-year increase of 18436.68%. This contributed to the annual value of $35.5 million for FY2024, which is 23964.95% up from last year.
  • TransMedics' Income towards Parent Company amounted to $24.3 million in Q3 2025, which was up 47711.1% from $34.9 million recorded in Q2 2025.
  • TransMedics' Income towards Parent Company's 5-year high stood at $34.9 million during Q2 2025, with a 5-year trough of -$25.4 million in Q3 2023.
  • For the 5-year period, TransMedics' Income towards Parent Company averaged around $744263.2, with its median value being -$2.6 million (2023).
  • Per our database at Business Quant, TransMedics' Income towards Parent Company crashed by 24233.77% in 2023 and then soared by 131818.18% in 2024.
  • Quarter analysis of 5 years shows TransMedics' Income towards Parent Company stood at -$12.8 million in 2021, then soared by 45.58% to -$7.0 million in 2022, then surged by 152.56% to $3.7 million in 2023, then skyrocketed by 87.58% to $6.9 million in 2024, then skyrocketed by 254.01% to $24.3 million in 2025.
  • Its Income towards Parent Company was $24.3 million in Q3 2025, compared to $34.9 million in Q2 2025 and $25.7 million in Q1 2025.